Form 4: Recursion Pharmaceuticals Director Acquires Shares Under Compensation Policy
SEC Form 4
R. Martin Chavez, a director at Recursion Pharmaceuticals, acquired 2,001 shares of Class A Common Stock on April 1, 2024, under the company's Outside Director Compensation Policy.
Summary
- On April 1, 2024, R. Martin Chavez, a director of Recursion Pharmaceuticals, acquired 2,001 shares of Class A Common Stock.
- The acquisition was made under the Issuer's Outside Director Compensation Policy.
- Following the transaction, Chavez directly owns 60,078 shares of Class A Common Stock.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive as it reflects a director's continued investment in the company through a standard compensation policy.
Positives
- The acquisition of shares by a director demonstrates confidence in the company.
Industry Context
This is a routine disclosure related to director compensation and is common in publicly traded companies.
Stakeholder Impact
- The transaction may have a minor positive impact on shareholder sentiment due to the director's increased stake in the company.
Key Dates
| Date | Description |
|---|---|
| 04/01/2024 | Date of transaction: R. Martin Chavez acquired 2,001 shares of Class A Common Stock. |
| 04/03/2024 | Date of signature: Form 4 signed by Jonathan Golightly, attorney-in-fact. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.